Founder and Director @ RosettaPath Ltd | Digital, Toxicologic, Experimental Pathology
N-nitrosodimethylamine (NDMA) has been identified as a contamination impurity in some commonly used pharmaceuticals, and this has resulted in several drug recalls by regulatory authorities. To improve evidence-based risk assessment, more experimental data is required to understand the link between NDMA exposure, mutation frequency and the sequence of events which may lead to the adverse outcome of carcinogenesis. I’m very pleased to have contributed along with other authors to this recent open access publication. From a pathology perspective, one point of interest was comparing the NDMA-related increased incidence of Ki67-positive hepatocytes, evaluated using a Halo AI-phenotyper model and the increase in mitoses evaluated manually across the different treatment groups. Thanks to @DeonHildebrand for expert help developing the Halo image analysis algorithm!
I am delighted to share our new publication in Mutagenesis. I want to thank and acknowledge the contributions of my co-authors and various lab scientists behind this work. The article is open access. N-Nitrosodimethylamine investigations in Muta™Mouse define point-of-departure values and demonstrate less-than-additive somatic mutant frequency accumulations Anthony M Lynch, Jonathan Howe, Deon Hildebrand, James S Harvey, Mark Burman, Danielle S G Harte, Liangfu Chen, Casey Kmett, Wei Shi, Charles F McHugh, Kinnari K Patel, Venkat Junnotula, Julia Kenny, Richard Haworth, John W Wills Mutagenesis, Volume 39, Issue 2, April 2024, Pages 96–118, https://lnkd.in/eVEVJWBs see: https://lnkd.in/e6gETPwJ
